R
Ryotaro Nakamura
Researcher at City of Hope National Medical Center
Publications - 272
Citations - 7696
Ryotaro Nakamura is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 35, co-authored 193 publications receiving 6019 citations. Previous affiliations of Ryotaro Nakamura include Beckman Research Institute & Biogen Idec.
Papers
More filters
Journal ArticleDOI
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Peter Hillmen,Neal S. Young,Jörg Schubert,Robert A. Brodsky,Gérard Socié,Petra Muus,Alexander Röth,Jeff Szer,Modupe O. Elebute,Ryotaro Nakamura,Paul Browne,Antonio M. Risitano,Anita Hill,Hubert Schrezenmeier,Chieh Lin Fu,Jaroslaw P. Maciejewski,Scott A. Rollins,Christopher F. Mojcik,Russell P. Rother,Lucio Luzzatto +19 more
TL;DR: Eculizumab is an effective therapy for PNH and Clinically significant improvements were found in the quality of life, as measured by scores on the Functional Assessment of Chronic Illness Therapy-Fatigue instrument and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.
Book
Hematopoietic Cell Transplantation
TL;DR: Hematopoietic cell transplantation is the IV infusion of hematopoetic stem and progenitor cells designed to establish marrow and immune function in patients with a variety of acquired and inherited malignant and nonmalignant disorders.
Journal ArticleDOI
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
Stefan O. Ciurea,Mei-Jie Zhang,Andrea Bacigalupo,Asad Bashey,Frederick R. Appelbaum,Omar S. Aljitawi,Philippe Armand,Joseph H. Antin,Junfang Chen,Steven M. Devine,Daniel H. Fowler,Leo Luznik,Ryotaro Nakamura,Paul O'Donnell,Miguel-Angel Perales,Sai Ravi Pingali,David L. Porter,Marcie L. Riches,Olle Ringdén,Vanderson Rocha,Ravi Vij,Daniel J. Weisdorf,Richard E. Champlin,Mary M. Horowitz,Ephraim J. Fuchs,Mary Eapen +25 more
TL;DR: It is suggested that survival for patients with AML after haploidentical transplantation with posttransplant cyclophosphamide is comparable with matched unrelated donor transplantation.
Journal ArticleDOI
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
David B. Miklos,Corey Cutler,Mukta Arora,Edmund K. Waller,Madan Jagasia,Iskra Pusic,Mary E.D. Flowers,Aaron C Logan,Ryotaro Nakamura,Bruce R. Blazar,Yunfeng Li,Stephen Chang,Indu D. Lal,Jason A. Dubovsky,Danelle F. James,Lori Styles,Samantha Jaglowski +16 more
TL;DR: Ibrutinib resulted in clinically meaningful responses with acceptable safety in patients with ≥1 prior treatments for cGV HD, and was approved in the United States for treatment of adult patients with cGVHD after failure of 1 or more lines of systemic therapy.
Journal ArticleDOI
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide
Asad Bashey,Mei-Jie Zhang,Shannon R. McCurdy,Andrew St. Martin,Trevor Argall,Claudio Anasetti,Stefan O. Ciurea,Omotayo Fasan,Sameh Gaballa,Mehdi Hamadani,Pashna N. Munshi,Monzr M. Al Malki,Ryotaro Nakamura,Paul O'Donnell,Miguel-Angel Perales,Kavita Raj,Rizwan Romee,Scott D. Rowley,Scott D. Rowley,Vanderson Rocha,Rachel B. Salit,Melhem Solh,Robert J. Soiffer,Ephraim J. Fuchs,Mary Eapen +24 more
TL;DR: PB and BM grafts are suitable for haploidentical transplantation with the post-transplant cyclophosphamide approach but with differing patterns of treatment failure, and must be validated in a randomized prospective comparison with adequate follow-up.